Your 2022 wildcard predictions revealed
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Roxadustat shows the latest regulatory fault line split
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.
The moral battle lines are drawn in Alzheimer’s
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
After the Aduhelm euphoria, reality bites
The practicalities of actually selling the controversial new Alzheimer’s drug are proving increasingly difficult for Biogen.
Biopharma takeovers dry up
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
Three days of reckoning for checkpoint blockers
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
